IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-25479-6.html
   My bibliography  Save this article

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

Author

Listed:
  • Timothy A. Bates

    (Oregon Health & Science University (OHSU))

  • Hans C. Leier

    (Oregon Health & Science University (OHSU))

  • Zoe L. Lyski

    (Oregon Health & Science University (OHSU))

  • Savannah K. McBride

    (Oregon Health & Science University (OHSU))

  • Felicity J. Coulter

    (Oregon Health & Science University (OHSU))

  • Jules B. Weinstein

    (Oregon Health & Science University (OHSU))

  • James R. Goodman

    (Medical Scientist Training Program, OHSU)

  • Zhengchun Lu

    (Oregon Health & Science University (OHSU))

  • Sarah A. R. Siegel

    (OHSU-PSU School of Public Health, Program in Epidemiology)

  • Peter Sullivan

    (OHSU-PSU School of Public Health, Program in Epidemiology)

  • Matt Strnad

    (OHSU-PSU School of Public Health, Program in Epidemiology)

  • Amanda E. Brunton

    (OHSU-PSU School of Public Health, Program in Epidemiology)

  • David X. Lee

    (Oregon Health & Science University (OHSU))

  • Andrew C. Adey

    (OHSU
    Knight Cardiovascular Institute, OHSU)

  • Benjamin N. Bimber

    (Vaccine and Gene Therapy Institute, OHSU)

  • Brian J. O’Roak

    (OHSU)

  • Marcel E. Curlin

    (OHSU)

  • William B. Messer

    (Oregon Health & Science University (OHSU)
    OHSU-PSU School of Public Health, Program in Epidemiology
    OHSU)

  • Fikadu G. Tafesse

    (Oregon Health & Science University (OHSU))

Abstract

SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough.

Suggested Citation

  • Timothy A. Bates & Hans C. Leier & Zoe L. Lyski & Savannah K. McBride & Felicity J. Coulter & Jules B. Weinstein & James R. Goodman & Zhengchun Lu & Sarah A. R. Siegel & Peter Sullivan & Matt Strnad &, 2021. "Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum," Nature Communications, Nature, vol. 12(1), pages 1-7, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25479-6
    DOI: 10.1038/s41467-021-25479-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-25479-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-25479-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. de León, Ugo Avila-Ponce & Avila-Vales, Eric & Huang, Kuan-lin, 2022. "Modeling COVID-19 dynamic using a two-strain model with vaccination," Chaos, Solitons & Fractals, Elsevier, vol. 157(C).
    2. Andrew P. Hederman & Harini Natarajan & Leo Heyndrickx & Kevin K. Ariën & Joshua A. Wiener & Peter F. Wright & Evan M. Bloch & Aaron A. R. Tobian & Andrew D. Redd & Joel N. Blankson & Amihai Rottenstr, 2023. "SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations," Nature Communications, Nature, vol. 14(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25479-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.